UTSW-led study shows promise for upper urinary tract cancer drug

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

In 1999, Richard Pazdur, a GI oncologist at MD Anderson, saw an FDA recruitment ad in The New England Journal of Medicine. The agency was looking for a director of the FDA Division of Oncology Drug Products.

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

A retrospective cohort study in women with breast cancer suggests that low oral doses of minoxidil taken during or after cancer treatment appear to regrow hair in most patients without causing any serious heart-related side effects that require additional therapies or hospitalization.

January 10, 2025

Vol.51 No.01

Clinical Roundup

UTSW scientists link hematopoietic cell transplant deaths to beta-blocker use

Patients can die if they take certain previously prescribed beta-blockers during a hematopoietic cell transplant due to suppressed signals from nerves that promote bone marrow regeneration, according to scientists at the Children’s Medical Center Research Institute at UT Southwestern, published in Cancer Discovery, builds upon previous CRI research by analyzing retrospective patient data to correlate beta-blocker use with significantly worse patient outcomes.

January 10, 2025

Vol.51 No.01

Clinical Roundup

UTSW scientists identify cancer-suppressing genetic mutation

UT Southwestern Medical Center researchers identified a genetic mutation that slows the growth of melanoma and potentially other cancers by harnessing the power of the immune system.

January 10, 2025

Vol.51 No.01

Clinical Roundup

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

Agendia Inc. announced it will be presenting new data from the Real-World Data Registry, FLEX, demonstrating MammaPrint’s ability to predict chemotherapy benefit in patients with HR+HER2- early-stage breast cancer. The findings will be presented at the San Antonio Breast Cancer Symposium 2024. The MammaPrint test analyzes the 70 most important genes associated with breast cancer recurrence.

December 13, 2024

Vol.50 No.46

Clinical Roundup

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

Timothy S. Fenske, Medical College of Wisconsin, presented findings from the ECOG-ACRIN phase III study EA4151, investigating rituximab with or without stem cell transplant in patients With minimal residual disease-negative mantle cell lymphoma in first complete remission, at the 66th ASH Annual Meeting and Exposition in San Diego.

December 13, 2024

Vol.50 No.46

UTSW-led study shows promise for upper urinary tract cancer drug

YOU MAY BE INTERESTED IN

After 25 years as FDA’s chief cancer strategist, Richard Pazdur reflects on opportunities for change at the agency

Hair growth drug safe at low doses for breast cancer patients, retrospective cohort study shows

UTSW scientists link hematopoietic cell transplant deaths to beta-blocker use

UTSW scientists identify cancer-suppressing genetic mutation

MammaPrint test demonstrates utility in predicting chemotherapy benefit over five years

High-dose chemo + autologous stem cell therapy demonstrates no benefit in MRD-negative mantle-cell lymphoma, phase III study shows

Renew today!

Subscriber content

Never miss an issue!

Login